This company has been acquired
Imago BioSciences (IMGO) Stock Overview
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IMGO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Imago BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.01 |
| 52 Week High | US$36.09 |
| 52 Week Low | US$11.56 |
| Beta | 0 |
| 1 Month Change | 0.39% |
| 3 Month Change | 134.29% |
| 1 Year Change | 80.50% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 121.06% |
Recent News & Updates
Recent updates
Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth Plans
Nov 08
Imago BioSciences GAAP EPS of -$0.41 beats by $0.09
Aug 12Here's Why We're Not Too Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Situation
Jul 26Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In Growth
Apr 12We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Rate
Dec 08Shareholder Returns
| IMGO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.1% | -0.2% | 3.3% |
| 1Y | 80.5% | 40.4% | 28.1% |
Return vs Industry: IMGO exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: IMGO exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| IMGO volatility | |
|---|---|
| IMGO Average Weekly Movement | 30.3% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: IMGO's share price has been volatile over the past 3 months.
Volatility Over Time: IMGO's weekly volatility has increased from 18% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 41 | Hugh Rienhoff | www.imagobio.com |
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Imago BioSciences, Inc. Fundamentals Summary
| IMGO fundamental statistics | |
|---|---|
| Market cap | US$1.22b |
| Earnings (TTM) | -US$61.64m |
| Revenue (TTM) | n/a |
Is IMGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMGO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$61.64m |
| Earnings | -US$61.64m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.82 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMGO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/12 07:47 |
| End of Day Share Price | 2023/01/10 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Imago BioSciences, Inc. is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Schmidt | Guggenheim Securities, LLC |
| Mitchell Kapoor | H.C. Wainwright & Co. |
| Maurice Raycroft | Jefferies LLC |